Quick Answer
Inhibitor Therapeutics, Inc. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2025.
Inhibitor Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.02 | +0.0% |
| 2024 | -$0.02 | +0.0% |
| 2023 | -$0.02 | -166.7% |
| 2022 | $0.03 | — |
| 2021 | $0.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | — |
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | — | — |
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | — |
- Inhibitor Therapeutics, Inc. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- The most recent figure is from Inhibitor Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: